REG - GSK PLC - Director/PDMR Shareholding
12/02/2024 15:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240212:nRSL8633Ca&default-theme=true
RNS Number : 8633C GSK PLC 12 February 2024
GSK plc (the 'Company')
Deferred Annual Bonus Plan Awards
On 8 February 2024, the Company granted awards to the Persons Discharging
Managerial Responsibilities ('PDMRs') listed below. The awards have been
granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred
Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.
Executive Directors and other members of the GSK Leadership Team are required
to defer part of any bonus earned into Ordinary Shares or American Depositary
Shares ('ADS') for three years. Under the terms of the Remuneration Policy
approved by shareholders in 2022, Executive Directors are required to defer
50% of bonus equivalent to the first 200% of salary into Ordinary Shares or
ADS with any portion in excess of 200% being deferred in full. Other members
of the GSK Leadership Team are required to defer 25% of bonus equivalent to
the first 170% of salary into Ordinary Shares or ADS with any portion in
excess of 170% being deferred in full.
The awards have been granted as restricted awards over ADS for US participants
and as nil-cost options over Ordinary Shares for all other participants.
The numbers of Ordinary Shares and ADS shown below are exclusive of dividend
reinvestment that will accrue during the deferral period.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 147,271
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 56,190
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 37,145
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 37,593
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 23,289
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 69,955
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction Deferred Bonus Award of ADS under the GlaxoSmithKline 2017 Deferred Annual
Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$42.02 17,987
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 44,528
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 53,627
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 29,991
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, GSK Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 46,391
.
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017
Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.726 57,148
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-08
f) Place of the transaction N/A
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFIFIEELSEEERecent news on GSK
See all newsREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK announces additional EAGLE-1 results
AnnouncementREG - GSK PLC - Results from long-term data relating to Shingrix
Announcement